Recent Work
-
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Categorized in -
Schaeffer Research Director Testifies at Congressional Hearing on Biomedical Innovation and Patient Access
Darius Lakdawalla was part of a panel of experts called upon by the U.S. House Ways and Means Subcommittee on Health.
-
Medicare Coverage of Weight Loss Drugs Could Significantly Reduce Costs
USC Schaeffer white paper finds that increasing access to obesity treatments would help save lives and reduce healthcare costs.
Categorized in -
New Schaeffer White Paper Offers Solutions to Ensure Greater Patient Access to Prescription Drugs
The researchers propose three strategies for mitigating negative impacts of the Inflation Reduction Act to ensure greater patient access, increased innovation and lower costs.
Categorized in -
Senate Finance Committee Explores Costly, Secretive Practices in the Drug Supply Chain
Karen Van Nuys testified at the hearing, calling transparency “an essential first step.”